Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital (MGH) on the effects of psilocybin-assisted psychotherapy for adults with Irritable B
Dunshaughlin prepares to say farewell to Denis Kealy meathchronicle.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from meathchronicle.ie Daily Mail and Mail on Sunday newspapers.
Tryp Therapeutics is seeking approval from U.S. regulators for a clinical trial on psilocybin-assisted therapy to help those with irritable bowel syndrome (IBS).